Schizophrenia Daily News Blog

Iloperidone Medications Update

Iloperidone Update - Antipsychotic Medication in Development

Iloperidone is a proprietary antipsychotic agent in Phase III clinical development for the treatment of schizophrenia and related psychotic disorders.

Vanda Pharmaceuticals, Inc., which acquired the worldwide rights to develop and commercialize iloperidone from Novartis Pharma AG, is now pursuing the advancement of the iloperidone Phase III development program, and is expected to initiate Phase III clinical testing of iloperidone later this year.

Vanda was founded by Dr. Argeris N. Karabelas, former CEO of Novartis Pharmaceuticals, and Dr. Mihael Polymeropoulos, former Vice President of Pharmacogenetics at Novartis Pharmaceuticals.

Source: Press/Marketing release from Titan Pharmaceuticals, Inc.